-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $112

Benzinga·12/09/2025 12:13:24
Listen to the news
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $71 to $112.